Pharma companies aim to halve CAR-T therapy production time

Original Article by Michael Erman | Reuters | 24 July 2024

Big pharma giants are cutting CAR-T therapy manufacturing time to expand access for aggressive cancer patients, aiming for faster, life-extending treatments.

Big pharma giants are cutting CAR-T therapy manufacturing time to expand access for aggressive cancer patients, aiming for faster, life-extending treatments.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here